```
Set     Items   Description
S1     180606   LACTOBACILLUS
S2         12   S1 AND PROTEASE (1W) MATURATION (1W) PROTEIN
S3         12   RD (unique items)
? s lactobacillus and pmp
          180606  LACTOBACILLUS
           21468  PMP
      S4      16  LACTOBACILLUS AND PMP
? rd
>>>Duplicate detection is not supported for File 398.
>>>Duplicate detection is not supported for File 654.
>>>Duplicate detection is not supported for File 349.
>>>Duplicate detection is not supported for File 348.
>>>Duplicate detection is not supported for File 340.
>>>Duplicate detection is not supported for File 390.
>>>Duplicate detection is not supported for File 347.
>>>Duplicate detection is not supported for File 446.
>>>Duplicate detection is not supported for File 342.
>>>Duplicate detection is not supported for File 345.
>>>Duplicate detection is not supported for File 181.
>>>Duplicate detection is not supported for File 324.
>>>Duplicate detection is not supported for File 391.
>>>Duplicate detection is not supported for File 393.
>>>Duplicate detection is not supported for File 767.
>>>Duplicate detection is not supported for File 344.
>>>Duplicate detection is not supported for File 286.

>>>Records from unsupported files will be retained in the RD set.
...completed examining records
      S5      15  RD (unique items)
? t s5/3,ab/1-15
>>>No matching display code(s) found in file(s): 65, 135, 181, 342, 345,
   390-391, 398, 446, 767

 5/3,AB/1     (Item 1 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) Format only 2005 The Dialog Corp. All rts. reserv.

0005551169
Derwent Accession: 2002-426107
Chlamydia %pmp% proteins, gene sequences and uses thereof
Inventor: Jackson, W., INV
Correspondence Address: PENNIE AND EDMONDS, 1155 AVENUE OF THE AMERICAS,
    NEW YORK, NY, 100362711

              Publication                    Application    Filing
                 Number     Kind   Date       Number        Date
              -------------  --  --------  -------------  --------
Main Patent   US 20040037846  A1  20040226  US 2003398248   20030801
PCT


Fulltext Word Count: 40391

Abstract:
    The invention discloses the Chlamydia PMPE and PMPI polypeptide,
  polypeptides derived therefrp, (%PMP%-derived polypeptides), nucleotide
  sequences encoding said polypeptides, antibodies that specifically bind
  the %PMP% polypeptides and %PMP%-derived polypeptides and T-cells
  specific for %PMP% polypeptides and %PMP%-derived polypeptides. Also
  disclosed are prophylactic and therapeutic compositions, including
  immunogenic compositions, e.g., vaccines, comprising %PMP% polypeptides
  or %PMP%-derived polypeptides or antibodies thereto. The invention
  additionally discloses methods of inducing in animals an immune response
  to Chlamydia cells, Chlamydia elementary bodies, and/or cells expressing
  Chlamydial proteins, e.g., cell infected with Chlamydia
```

5/3,AB/2 (Item 2 from file: 654)
DIALOG(R)File 654:US Pat.Full.

0005494099
Derwent Accession: 2002-154726
Immunisation against chlamydia pneumoniae
Inventor: Ratti, Giuloi, INV
Grandi, Guido, INV
Correspondence Address: Rebecca Hale Chiron Corporation, Intellectual Property Law Department R 3 PO Box 8097, Emeryville, CA, 94662-8097, US

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 20040005667	A1	20040108	US 2003312273	20030505
PCT					
Priority				GB 200016363	20000703
				GB 200017047	20000711
				GB 200017938	20000721
				GB 200019368	20000807
				GB 200020440	20000818
				GB 200022583	20000914
				GB 200027549	20001110
				GB 200031706	20001222

Fulltext Word Count: 46188

Abstract:
The published genomic of Chlamydia pneumoniae reveals over 1000 putative encoded proteins but does not itself indicate which of these might to useful antigens for immunisation and vaccination or for diagnosis. This difficulty is addressed by the invention, which provides a number of C. pneumoniae protein sequences suitable for vaccine production and development and/or for diagnostic purposes.

5/3,AB/3 (Item 1 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT

01114910
METHODS AND ORGANISMS FOR PRODUCTION OF B6 VITAMERS
METHODES ET ORGANISMES POUR LA PRODUCTION DE VITAMERES B6
Patent Applicant/Assignee:
BASF AKTIENGESELLSCHAFT, 67056 Ludwigshafen, DE, DE (Residence), DE (Nationality), (For all designated states except: US)
Patent Applicant/Inventor:
YOCUM Rogers R, 4 Orchard Lane, Lexington, MA 02420, US, US (Residence), US (Nationality), (Designated only for: US)
WILLIAMS Mark K, 58 School Street, Revere, MA 02151, US, US (Residence), US (Nationality), (Designated only for: US)
PERO Janice G, 20 Solomon Pierce Road, Lexington, MA 02420, US, US (Residence), US (Nationality), (Designated only for: US)
Legal Representative:
HANLEY Elizabeth A (et al) (agent), Lahive & Cockfield, LLP, 28 State Street, Boston, MA 02109, US,
Patent and Priority Information (Country, Number, Date):
Patent: WO 200435010 A2 20040429 (WO 0435010)
Application: WO 2003US8880 20030321 (PCT/WO US03008880)
Priority Application: US 2002367089 20020322; US 2002367863 20020325; US 2002368618 20020329; US 2003451824 20030303
Designated States:
(Protection type is "patent" unless otherwise stated - for applications prior to 2004)

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ
EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR
LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG
SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW
(EP) AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE
SI SK TR
(OA) BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
(EA) AM AZ BY KG KZ MD RU TJ TM
Publication Language: English
Filing Language: English
Fulltext Word Count: 19530

English Abstract
The present invention features methods of producing B6 vitamers that involve culturing an organism overexpressing an enzyme that catalyzes a step in the biosynthesis of a B6 vitamer under conditions such that a B6 vitamer is produced. The present invention further features methods of producing B6 vitamers that involve culturing recombinant microorganisms having increased activity of at least one B6 vitamer biosynthetic enzyme, e.g., YaaD or YaaE, or a homologue thereof, or Epd, PdxA, PdxJ, PdxF, PdxB, PdxH, and/or Dxs , or a homologue thereof.

French Abstract
La presente invention concerne des methodes de production de vitameres B6 consistant a cultiver un organisme surexprimant une enzyme qui catalyse une etape dans la biosynthese d'un vitamere B6 dans des conditions permettant la production d'un vitamere B6. La presente invention concerne en outre des methodes de production de vitameres B6 consistant a cultiver des micro-organismes recombines presentant une activite accrue d'au moins une enzyme biosynthetique de vitamere B6, telle que YaaD ou YaaE, ou d'un homologue correspondant, ou de Epd, PdxA, PdxJ, PdxF, PdxB, PdxH et/ou Dxs, ou d'un homologue correspondant.

5/3,AB/4 (Item 2 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT

00994443
NOVEL NUCLEIC ACIDS AND POLYPEPTIDES
NOUVEAUX ACIDES NUCLEIQUES ET POLYPEPTIDES
Patent Applicant/Assignee:
NUVELO INC, 675 Almanor Avenue, Sunnyvale, CA 94085, US, US (Residence), US (Nationality), (For all designated states except: US)
Patent Applicant/Inventor:
TANG Y Tom, 4230 Ranwick Court, San Jose, CA 95118, US, US (Residence), US (Nationality), (Designated only for: US)
YANG Yonghong, 4230 Ranwick Court, San Jose, CA 95118, US, US (Residence), CN (Nationality), (Designated only for: US)
WANG Zhi Wei, 1130 Founders Boulevard, Athens, GA 30606, US, US (Residence), CN (Nationality), (Designated only for: US)
WENG Gezhi, 415 Moraga Avenue, Piedmont, CA 94611, US, US (Residence), US (Nationality), (Designated only for: US)
MA Yunqing, 3670 Tamarack In., Apt 36, Santa Clara, CA 95051, US, US (Residence), CN (Nationality), (Designated only for: US)
Legal Representative:
POLIZOTTO Renee (agent), Nuvelo, Inc., 675 Almanor Avenue, Sunnyvale, CA 94085, US,
Patent and Priority Information (Country, Number, Date):
Patent: WO 200323013 A2-A3 20030320 (WO 0323013)
Application: WO 2002US29001 20020913 (PCT/WO US0229001)
Priority Application: US 2001322511 20010913; US 2002243552 20020912
Parent Application/Grant:
Related by Continuation to: US 2001322511 20010913 (CIP); US 2002243552 20020912 (CIP)
Designated States:
(Protection type is "patent" unless otherwise stated - for applications

prior to 2004)
AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ
EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR
LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI
SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW
(EP) AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR
(OA) BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
(EA) AM AZ BY KG KZ MD RU TJ TM
Publication Language: English
Filing Language: English
Fulltext Word Count: 99574

English Abstract
The present invention provides novel nucleic acids, novel polypeptide sequences encoded by these nucleic acids and uses thereof.

French Abstract
L'invention concerne de nouveaux acides nucleiques, de nouvelles sequences polypeptidiques codees par ces acides nucleiques, et l'utilisation de ceux-ci.

5/3,AB/5 (Item 3 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT

00895045
CHLAMYDIA %PMP% PROTEINS, GENE SEQUENCES AND USES THEREOF
PROTEINES %PMP% DE CHLAMYDIA, SEQUENCES DE GENE ET UTILISATION DE CELLES-CI
Patent Applicant/Assignee:
ANTEX BIOLOGICS INC, 300 Professional Drive, Gaithersburg, MD 20879, US, US (Residence), US (Nationality), (For all designated states except: US)
Patent Applicant/Inventor:
JACKSON W James, 1687 Armistice Way, Marriottsville, MD 21104, US, US (Residence), US (Nationality), (Designated only for: US)
Legal Representative:
BALDWIN Geraldine F (et al) (agent), Pennie & Edmonds LLP, 1155 Avenue of the Americas, New York, NY 10036, US,
Patent and Priority Information (Country, Number, Date):
Patent: WO 200228998 A2-A3 20020411 (WO 0228998)
Application: WO 2001US30345 20010928 (PCT/WO US0130345)
Priority Application: US 2000677752 20001002
Designated States:
(Protection type is "patent" unless otherwise stated - for applications prior to 2004)
AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ
EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR
LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK
SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
(OA) BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZW
(EA) AM AZ BY KG KZ MD RU TJ TM
Publication Language: English
Filing Language: English
Fulltext Word Count: 36905

English Abstract
The invention discloses the Chlamydia PMPE and PMPI polypeptide, polypeptides derived therefor, (%PMP%-derived polypeptides), nucleotide sequences encoding said polypeptides, antibodies that specifically bind the %PMP% polypeptides and %PMP%-derived polypeptides and T-cells specific for %PMP% polypeptides and %PMP%-derived polypeptides. Also disclosed are prophylactic and therapeutic compositions, including immunogenic compositions, e.g., vaccines, comprising %PMP% polypeptides or %PMP%-derived polypeptides or antibodies thereto. The invention

additionally discloses methods of inducing in animals an immune response to Chlamydia cells, Chlamydia elementary bodies, and/or cells expressing Chlamydial proteins, e.g., cell infected with Chlamydia.

French Abstract
La presente invention concerne le polypeptide PMPE et PMPI de chlamydia, des polypeptides derives de celui-ci (polypeptides derives de %PMP%), des sequences nucleotidiques codantes pour ces polypeptides, des anticorps qui se lient specifiquement a ces polypeptides %PMP% et a ces polypeptides derives de %PMP% et des lymphocytes T specifiques pour ces polypeptides %PMP% et ces polypeptides derives de %PMP%. Cette invention concerne aussi des compositions prophylactiques et therapeutiques, comprenant des composition immunogenes, par exemple des vaccins, comprenant ces polypeptides %PMP%, ces polypeptides derives de %PMP% ou des anticorps de ceux-ci. Cette invention concerne enfin des techniques permettant d'induire chez des animaux une reponse immunitaire des cellules a chlamydia, des corps elementaires de chlamydia, et/ou des cellules exprimant les proteines de chlamydia, par exemple une cellule infectee par chlamydia.

5/3,AB/6 (Item 4 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT

00868740
IMMUNISATION AGAINST CHLAMYDIA PNEUMONIAE
IMMUNISATION CONTRE UNE INFECTION PAR CHLAMYDIA PNEUMONIAE
Patent Applicant/Assignee:
CHIRON S P A, Via Fiorentina, 1, I-53100 Siena, IT, IT (Residence), IT (Nationality), (For all designated states except: US)
Patent Applicant/Inventor:
RATTI Giulio, Chiron S.p.A., Via Fiorentina, 1, I-53100 Siena, IT, IT (Residence), IT (Nationality), (Designated only for: US)
GRANDI Guido, Chiron S.p.A., Via Fiorentina, 1, I-53100 Siena, IT, IT (Residence), IT (Nationality), (Designated only for: US)
Legal Representative:
HALLYBONE Huw George (et al) (agent), Carpmaels & Ransford, 43 Bloomsbury Square, London WC1A 2RA, GB,
Patent and Priority Information (Country, Number, Date):
Patent: WO 200202606 A2-A3 20020110 (WO 0202606)
Application: WO 2001IB1445 20010703 (PCT/WO IB0101445)
Priority Application: GB 200016363 20000703; GB 200017047 20000711; GB 200017983 20000721; GB 200019368 20000807; GB 200020440 20000818; GB 200022583 20000914; GB 200027549 20001110; GB 200031706 20001222
Designated States:
(Protection type is "patent" unless otherwise stated - for applications prior to 2004)
AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZW
(EA) AM AZ BY KG KZ MD RU TJ TM
Publication Language: English
Filing Language: English
Fulltext Word Count: 79446

English Abstract
The genomic of Chlamydia pneumoniae reveals over 1000 putative encoded proteins. The invention provides a number of C. pneumoniae protein sequences suitable for vaccine production and development and/or for diagnostic purposes.

French Abstract
La sequence genomique publiee de Chlamydia pneumoniae presente

plus de 1000 proteines possibles codees, mais n'indique pas elle-meme les protéines pouvant etre utilisees comme antigenes pour une immunisation, une vaccination ou un diagnostic. Cette difficulte est surmontee par l'invention qui fournit un certain nombre de sequences proteiniques de C. pneumoniae appropriees pour developper et produire des vaccins et/ou pour etablir un diagnostic.

5/3,AB/7 (Item 5 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT

00794925
LANTIBIOTIC
LANTIBIOTIQUE
Patent Applicant/Assignee:
UNIVERSITY OF OTAGO, Leith Street, Dunedin, NZ, NZ (Residence), NZ (Nationality), (For all designated states except: US)
BLIS TECHNOLOGIES LIMITED, Level 10, Otago House, 481 Moray Place, Dunedin, NZ, NZ (Residence), NZ (Nationality), (For all designated states except: US)
Patent Applicant/Inventor:
TAGG John Robert, 39 Braeview Crescent, Dunedin, NZ, NZ (Residence), AU (Nationality), (Designated only for: US)
DIERKSEN Karen Patricia, c/- 3450 SW Campus Way, Corvallis, OR 97331-8539, US, US (Residence), US (Nationality), (Designated only for: US)
UPTON Mathew, Flat 1, 15 Peacock Street, Christchurch, NZ, NZ (Residence), GB (Nationality), (Designated only for: US)
Legal Representative:
BENNETT Michael Roy (et al) (agent), A J Park, Huddart Parker Building, 6th Floor, 1 Post Office Square, P.O. Box 949, Wellington 6015, NZ,
Patent and Priority Information (Country, Number, Date):
Patent: WO 200127143 A1 20010419 (WO 0127143)
Application: WO 2000NZ197 20001012 (PCT/WO NZ0000197)
Priority Application: NZ 500261 19991012
Designated States:
(Protection type is "patent" unless otherwise stated - for applications prior to 2004)
AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZW
(EA) AM AZ BY KG KZ MD RU TJ TM
Publication Language: English
Filing Language: English
Fulltext Word Count: 6963

English Abstract
This invention provides an antibacterial protein, salivaricin B. Salivaricin B is bacteriocidal with respect to, inter alia, S. pyogenes and therefore has numerous therapeutic applications. These applications include, but are not limited to, forming part of therapeutic formulations for use in treating or preventing streptococcal infections of the throat.

French Abstract
L'invention concerne une proteine antibacterienne, salivaricine B. Salivaricine B a une fonction bactericide, y compris vis-a-vis de S. pyogenes et possede de ce fait de nombreuses applications therapeutiques. Ces applications comprennent (mais non de facon exclusive) la creation de formulations therapeutiques utilisees dans le traitement ou la prevention des infections de la gorges par des streptocoques.

5/3,AB/8 (Item 6 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT

00780221
PNEUMOCOCCAL VACCINES
VACCINS ANTIPNEUMOCOCCIQUES
Patent Applicant/Assignee:
ERASMUS UNIVERSITEIT ROTTERDAM, Dr. Molewaterplein 50, NL-5015 GE Rotterdam, NL, NL (Residence), NL (Nationality), (For all designated states except: US)
Patent Applicant/Inventor:
DE GROOT Ronald, Jan Van Ghestellaan 45, NL-3045 CG Rotterdam, NL, NL (Residence), NL (Nationality), (Designated only for: US)
HERMANS Peter Wilhelmus Maria, Gortmolenerf 36, NL-2807 EJ Gouda, NL, NL (Residence), NL (Nationality), (Designated only for: US)
Legal Representative:
PRINS A W, Vereenigde, Nieuwe Parklaan 97, NL-2587 BN The Hague, NL
Patent and Priority Information (Country, Number, Date):
Patent: WO 200112219 A1 20010222 (WO 0112219)
Application: WO 2000NL569 20000814 (PCT/WO NL0000569)
Priority Application: EP 99202640 19990813
Designated States:
(Protection type is "patent" unless otherwise stated - for applications prior to 2004)
AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZW
(EA) AM AZ BY KG KZ MD RU TJ TM
Publication Language: English
Filing Language: English
Fulltext Word Count: 7578

English Abstract
The invention relates to the use of a protein or a fragment thereof of S. pneumoniae , its use for the preparation of a vaccine for the preventive treatment of a S. pneumoniae infection, compositions comprising protease maturation protein of S. pneumoniae infection, or a fragment thereof, vaccines comprising said protein or fragment thereof, use of a nucleic acid sequence encoding for said protein or fragment thereof, vectors wherein the nucleic acid sequence is brought to expression and to recombinant protease maturation protein or a fragment thereof or (functional) homologues thereof and to a method for the determination of proteins with opsonophagocytic activity and/or in vivo immunisation and/or in vivo immune protection.

French Abstract
L'invention concerne l'utilisation d'une proteine S. pneumoniae ou d'un fragment de celle-ci, son utilisation pour la preparation d'un vaccin pour le traitement preventif d'une infection a S. pneumoniae , des compositions comprenant la proteine de maturation de protease de S. pneumoniae ou un fragment de celle-ci, vaccins comprenant ladite proteine ou un fragment de celle-ci. L'invention porte egalement sur l'utilisation d'une sequence nucleotidique codant pour ladite proteine ou ledit fragment de celle-ci, sur des vecteurs dans lesquels l'expression de la sequence nucleotidique est transformee en proteine de maturation de protease recombinee, en un fragment de celle-ci ou en homologues (fonctionnels) de celle-ci. L'invention se rapporte encore a un procede de determination de proteines ayant une activite opsonophagocytique et/ou d'immunisation in vivo et/ou de protection immunitaire in vivo .

5/3,AB/9 (Item 7 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT

00577589
CYCLODEXTRIN POLYMERS FOR USE AS DRUG CARRIERS
POLYMERES DE CYCLODEXTRINE UTILISES SOUS FORME DE VECTEURS DE MEDICAMENTS
Patent Applicant/Assignee:
KOSAK Ken M,
Inventor(s):
KOSAK Ken M,
Patent and Priority Information (Country, Number, Date):
Patent: WO 200040962 A1 20000713 (WO 0040962)
Application: WO 99US30820 19991227 (PCT/WO US9930820)
Priority Application: US 98223055 19981230
Designated States:
(Protection type is "patent" unless otherwise stated - for applications prior to 2004)
AU BR CA CN IL IN JP MX AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
Publication Language: English
Fulltext Word Count: 21238

English Abstract
This invention discloses methods for preparing compositions of cyclodextrin polymers for carrying drugs and other active agents. Methods are also disclosed for preparing cyclodextrin polymer carriers that release drugs under controlled conditions. The invention also discloses methods for preparing compositions of cyclodextrin polymer carriers that are coupled to biorecognition molecules for targeting the delivery of drugs to their site of action. The advantages of the water-soluble (or colloidal) cyclodextrin polymer carrier are: 1) drugs can be used that are designed for efficacy without conjugation requirements; 2) it will allow the use of drugs designed solely for efficacy without regard for solubility; 3) unmodified drugs can be delivered as macromolecules and released within the cell; 4) drugs can be targeted by coupling the carrier to biorecognition molecules; 5) synthesis methods are independent of the drug to facilitate multiple drug therapies.

French Abstract
L'invention concerne des techniques permettant de preparer des compositions de polymeres de cyclodextrine qui portent des medicaments et d'autres principes actifs. Ces techniques sont egalement utilisees pour preparer des vecteurs de polymere de cyclodextrine qui liberent des medicaments dans des conditions controlees. L'invention concerne, en outre, des techniques permettant de preparer des vecteurs de polymere de cyclodextrine couples a des molecules de bioreconnaissance, afin de cibler la distribution des medicaments sur leur site d'action. Le vecteur de polymere de cyclodextrine soluble dans l'eau (ou colloidal) presente les avantages suivants: 1) on peut utiliser ces medicaments efficacement concus sans obligation de conjugaison; 2) on peut utiliser ces medicaments concus uniquement pour etre efficaces independamment de leur solubilite; 3) on peut administrer des medicaments non modifies sous forme de macromolecules et les liberer dans la cellule; 4) on peut cibler ces medicaments par couplage du vecteur avec des molecules de reconnaissance; 5) les techniques de synthese sont independantes du medicament, afin de faciliter d'autres therapies a l'aide dudit medicament.

5/3,AB/10 (Item 8 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT

00430875
METHOD FOR THE PRODUCTION OF 1,3-PROPANEDIOL BY RECOMBINANT ORGANISMS
PROCEDE DE PRODUCTION DE 1,3-PROPANEDIOL PAR DES ORGANISMES RECOMBINES
Patent Applicant/Assignee:
E I DU PONT DE NEMOURS AND COMPANY,
GENENCOR INTERNATIONAL INC,
GATENBY Anthony Arthur,
HAYNIE Sharon Loretta,

NAGARAJAN Vasantha,
NAIR Ramesh V,
NAKAMURA Charles E,
PAYNE Mark Scott,
PICATAGGIO Stephen Kenneth,
DIAS-TORRES Maria,
HSU Amy Kuang-Hua,
LAREAU Richard D,
TRIMBUR Donald E,
WHITED Gregory M,
Inventor(s):
GATENBY Anthony Arthur,
HAYNIE Sharon Loretta,
NAGARAJAN Vasantha,
NAIR Ramesh V,
NAKAMURA Charles E,
PAYNE Mark Scott,
PICATAGGIO Stephen Kenneth,
DIAS-TORRES Maria,
HSU Amy Kuang-Hua,
LAREAU Richard D,
TRIMBUR Donald E,
WHITED Gregory M,
Patent and Priority Information (Country, Number, Date):
Patent: WO 9821339 A1 19980522
Application: WO 97US20292 19971110 (PCT/WO US9720292)
Priority Application: US 9630601 19961113
Designated States:
(Protection type is "patent" unless otherwise stated - for applications prior to 2004)
AU BR CA CN ID IL JP KR MX SG US AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE
Publication Language: English
Fulltext Word Count: 30753
English Abstract
Recombinant organisms are provided comprising genes encoding glycerol-3-phosphate dehydrogenase, glycerol-3-phosphatase, glycerol dehydratase and 1,3-propanediol oxidoreductase activities useful for the production of 1,3-propanediol from a variety of carbon substrates.

French Abstract
Cette invention concerne des organismes recombines comportant des genes codant pour des activites de glycerol-3-phosphate deshydrogenase, de glycerol-3-phosphatase, de glycerol deshydratase et de 1,3-propanediol oxydoreductase. Ces organismes sont utiles a la production de 1, 3-propanediol a partir d'une pluralite de substrats carbones.

5/3,AB/11 (Item 9 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT

00353282
BIOCONVERSION OF A FERMENTABLE CARBON SOURCE TO 1,3-PROPANEDIOL BY A SINGLE MICROORGANISM
BIOCONVERSION D'UNE SOURCE DE CARBONE FERMENTESCIBLE EN 1,3-PROPANEDIOL PAR UN SEUL MICRO-ORGANISME
Patent Applicant/Assignee:
E I DU PONT DE NEMOURS AND COMPANY,
GENENCOR INTERNATIONAL INC,
LAFFEND Lisa Anne,
NAGARAJAN Vasantha,
NAKAMURA Charles Edwin,
Inventor(s):
LAFFEND Lisa Anne,
NAGARAJAN Vasantha,
NAKAMURA Charles Edwin,
Patent and Priority Information (Country, Number, Date):

Patent: WO 9635796 A1 19961114
Application: WO 96US6705 19960510 (PCT/WO US9606705)
Priority Application: US 95440293 19950512
Designated States:
(Protection type is "patent" unless otherwise stated - for applications prior to 2004)
AL AU BB BG BR CA CN CZ EE GE HU IS JP KP KR LK LR LT LV MG MK MN MX NO NZ PL RO SG SI SK TR TT UA US UZ VN KE LS MW SD SZ UG AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG
Publication Language: English
Fulltext Word Count: 30574

English Abstract
A process is provided for the bioconversion of a carbon substrate to 1,3-propanediol by a single organism utilizing microorganisms containing the genes encoding for an active glycerol or diol dehydratase enzyme by contacting these organisms with a carbon substrate under the appropriate fermentation conditions.

French Abstract
La presente invention concerne un procede de bioconversion d'un substrat de carbone en 1, 3-propanediol par un seul organisme utilisant des micro-organismes qui contiennent les genes codant pour donner un glycerol actif ou une enzyme dehydratase de diol, en mettant ces organismes au contact d'un substrat de carbone dans les conditions de fermentation appropriees.

5/3,AB/12 (Item 1 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

01245487
Pneumococcal vaccines
Pneumokokkus Impfstoffe
Vaccins pneumococciques
PATENT ASSIGNEE:
Erasmus Universiteit Rotterdam, (517671), Dr. Molewaterplein 50, 3015 GE Rotterdam, (NL), (Applicant designated States: all)
INVENTOR:
de Groot, Ronald, Jan van Ghestellaan 45, 3045 CG Rotterdam, (NL)
Hermans, Peter Wilhelmus Maria, Gortmolenerf 36, 2807 EJ Gouda, (NL)
LEGAL REPRESENTATIVE:
Ottevangers, Sietse Ulbe et al (20841), Vereenigde, Postbus 87930, 2508 DH Den Haag, (NL)
PATENT (CC, No, Kind, Date): EP 1075841 A1 010214 (Basic)
APPLICATION (CC, No, Date): EP 99202640 990813;
DESIGNATED STATES: DE
EXTENDED DESIGNATED STATES: AL; LT; LV; MK; RO; SI
INTERNATIONAL PATENT CLASS: A61K-039/09; C07K-014/315; C12N-015/31; C07K-016/12; A61P-031/04

ABSTRACT EP 1075841 A1
The invention relates to the use of a protein or a fragment thereof of S. pneumoniae, its use for the preparation of a vaccine for the preventive treatment of a S. pneumoniae infection, compositions comprising protease maturation protein of S. pneumoniae or a fragment thereof, vaccines comprising said protein or fragment thereof, use of a nucleic acid sequence encoding for said protein or fragment thereof, vectors wherein the nucleic acid sequence is brought to expression and to recombinant protease maturation protein or a fragment thereof.
ABSTRACT WORD COUNT: 86
NOTE:
Figure number on first page: NONE

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	200107	457
SPEC A	(English)	200107	5155
Total word count - document A			5612
Total word count - document B			0
Total word count - documents A + B			5612

5/3,AB/13 (Item 2 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

01132827
NOVEL METHODS FOR THE IDENTIFICATION OF LIGAND AND TARGET BIOMOLECULES
NEUE METHODEN ZUM AUFFINDEN VON LIGANDEN- UND ZIEL-BIOMOLEKULEN
NOUVELLES TECHNIQUES D'IDENTIFICATION DE LIGAND ET DE BIOMOLECULES CIBLES
PATENT ASSIGNEE:
Inoxell A/S, (3937780), Kogle Alle 5, 2970 Hoersholm, (DK), (Proprietor designated states: all)
INVENTOR:
HALKIER, Torben, Lyngvej 5, DK-2680 Solrod Strand, (DK)
JESPERSEN, Lene, Sorupvej 48, DK-3480 Fredensborg, (DK)
JENSEN, Allan, Praestemosevej 1, DK-3480 Fredensborg, (DK)
PATENT (CC, No, Kind, Date): EP 1098991 A1 010516 (Basic)
EP 1098991 B1 020911
WO 2000005406 000203
APPLICATION (CC, No, Date): EP 99932689 990716; WO 99DK408 990716
PRIORITY (CC, No, Date): DK 98956 980720; US 94868 P 980729
DESIGNATED STATES: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI; LU; MC; NL; PT; SE
EXTENDED DESIGNATED STATES: AL; LT; LV; MK; RO; SI
RELATED DIVISIONAL NUMBER(S) - PN (AN):
(EP 2002076171)
INTERNATIONAL PATENT CLASS: C12Q-001/68; C12N-015/10
NOTE:
No A-document published by EPO
LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	200237	1550
CLAIMS B	(German)	200237	1426
CLAIMS B	(French)	200237	1778
SPEC B	(English)	200237	21412
Total word count - document A			0
Total word count - document B			26166
Total word count - documents A + B			26166

5/3,AB/14 (Item 1 from file: 16)
DIALOG(R)File 16:Gale Group PROMT(R)

09176370 Supplier Number: 80023947
INGREDIENTS.(directory of food ingredient companies)(Directory)
Food Processing, v62, n10, p35
Oct, 2001
Language: English Record Type: Fulltext
Article Type: Directory
Document Type: Magazine/Journal; Trade
Word Count: 36874

5/3,AB/15 (Item 1 from file: 148)
DIALOG(R)File 148:Gale Group Trade & Industry DB

14030230 SUPPLIER NUMBER: 80023948 (USE FORMAT 7 OR 9 FOR FULL TEXT)
NUTRACEUTICAL COMPANIES.(directory)(Directory)

Food Processing, 62, 10, 69
Oct, 2001
DOCUMENT TYPE: Directory ISSN: 0015-6523 LANGUAGE: English
RECORD TYPE: Fulltext
WORD COUNT: 2323 LINE COUNT: 00226
?

```
xecuting TA40273423
Hilight option is not available in file(s) 398, 399
HILIGHT set on as '%'
      S1  180606  LACTOBACILLUS
? s s1 and protease (1w) maturation (1w) protein
Processing
Processed  10 of  60 files ...
Completed processing all files
          180606  S1
          707173  PROTEASE
          662519  MATURATION
        15747110  PROTEIN
              44  PROTEASE(1W)MATURATION(1W)PROTEIN
      S2      12  S1 AND PROTEASE (1W) MATURATION (1W) PROTEIN
? rd
>>>Duplicate detection is not supported for File 398.
>>>Duplicate detection is not supported for File 654.
>>>Duplicate detection is not supported for File 349.
>>>Duplicate detection is not supported for File 348.
>>>Duplicate detection is not supported for File 340.
>>>Duplicate detection is not supported for File 390.
>>>Duplicate detection is not supported for File 347.
>>>Duplicate detection is not supported for File 446.
>>>Duplicate detection is not supported for File 342.
>>>Duplicate detection is not supported for File 345.
>>>Duplicate detection is not supported for File 181.
>>>Duplicate detection is not supported for File 324.
>>>Duplicate detection is not supported for File 391.
>>>Duplicate detection is not supported for File 393.
>>>Duplicate detection is not supported for File 767.
>>>Duplicate detection is not supported for File 344.
>>>Duplicate detection is not supported for File 286.

>>>Records from unsupported files will be retained in the RD set.
...completed examining records
      S3      12  RD (unique items)
? t s3/3,ab/1-12
>>>No matching display code(s) found in file(s): 65, 135, 181, 342, 345,
   390-391, 398, 446, 767

 3/3,AB/1     (Item 1 from file: 5)
DIALOG(R)File   5:Biosis Previews(R)
(c) 2005 BIOSIS. All rts. reserv.

0009999546   BIOSIS NO.: 199598467379
Nucleotide sequence and characterization of peb4A encoding an antigenic
  protein in Campylobacter jejuni
AUTHOR: Burucoa C (Reprint); Fremaux Z; Pei Z; Tummuru M; Blaser M J;
  Cenatiempo Y; Fauchere J L
AUTHOR ADDRESS: Laboratoire de Microbiologie A, CHU La Miletrie, BP 577,
  86021 Poiters, France**France
JOURNAL: Research in Microbiology  146 (6): p467-476 1995 1995
ISSN: 0923-2508
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: The 29-kDa protein PEB4, a major antigen of Campylobacter jejuni,
  is present in all C. jejuni strains tested and elicits an antibody
  response in infected patients. By screening a lambda-gt11 library of
  chromosomal DNA fragments of C. jejuni strain 81-176 in Escherichia coli
  Y1090 cells with antibody raised against purified PEB4, a recombinant
  phage with a 2-kb insert expressing an immunoreactive protein of 29 kDa
  was isolated. DNA sequence analysis revealed that the insert contains two
  complete open reading frames ORF-A and ORF-B. ORF-A (peb4A) encodes a
  273-residue protein with a calculated molecular mass of 30,460 daltons.
  The deduced amino acid sequence, composition and pI of the recombinant
  mature protein are similar to those determined for purified PEB4. The
```

first 21 residues resemble a signal peptide. Gene bank searches indicated 33.7% identity with protein export protein PrsA of Bacillus subtilis and 23.8% identity with %protease% %maturation% %protein% precursor PrtM of Lactococcus lactis. PCR experiments indicate that peb4A is highly conserved among C. jejuni strains. ORF-B begins 2 bp after the last codon of peb4A and encodes a putative protein of 353 residues with 63.4% identity with E. coli fructose 1,6-biphosphate aldolase. The sequence arrangement suggests that these two genes form an operon.

3/3,AB/2 (Item 1 from file: 398)
DIALOG(R)File 398:Chemsearch
(c) 2005 Amer.Chem.Society All rts. reserv.

CAS REGISTRY NUMBER: 647192-71-0
MOLECULAR FORMULA: Unknown
CA NAME(S):
HP=Protease maturation protein precursor (Lactobacillus johnsonii strain NCC533) (9CI)
SYNONYMS: GenBank AAS09786; GenBank AAS09786 (Translated from: GenBank AE017206)

3/3,AB/3 (Item 2 from file: 398)
DIALOG(R)File 398:Chemsearch
(c) 2005 Amer.Chem.Soc. All rts. reserv.

CAS REGISTRY NUMBER: 647189-30-8
MOLECULAR FORMULA: Unknown
CA NAME(S):
HP=Protease maturation protein precursor (Lactobacillus johnsonii strain NCC533) (9CI)
SYNONYMS: GenBank AAS09446; GenBank AAS09446 (Translated from: GenBank AE017205)

3/3,AB/4 (Item 1 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) Format only 2005 The Dialog Corp. All rts. reserv.

0005386990
Derwent Accession: 2003-167404
Bacterial ghosts prvided with antigens
Inventor: Leenhouts, Cornelis, INV
Ramasamy, Ranjan, INV
Steen, Anton, INV
Kok, Jan, INV
Buist, Girbe, INV
Kuipers, Oscar, INV
Correspondence Address: TRASK BRITT, P.O. BOX 2550, SALT LAKE CITY, UT, 84110, US

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 20030186851	A1	20031002	US 2002318675	20021213
Continuation	UNKNOWN			WO 2002NL383	20020611
Priority				EP 2001202239	20010611

Fulltext Word Count: 17239

Abstract:
Methods for improving binding of a proteinaceous substance to cell-wall material of a Gram-positive bacterium are disclosed. The proteinaceous substance includes an AcmA cell-wall binding domain, homolog or functional derivative thereof. The method includes treating the cell-wall material with a solution capable of removing a cell-wall component such

as a protein, lipoteichoic acid or carbohydrate from the cell-wall material and contacting the proteinaceous substance with the cell-wall material.

3/3,AB/5 (Item 2 from file: 654)
DIALOG(R)File 654:US Pat.Full.

0005377142
Derwent Accession: 2003-167404
Method to provide bacterial ghosts provided with antigens
Inventor: Leenhouts, Cornelis, INV
Ramasamy, Ranjan, INV
Steen, Anton, INV
Kok, Jan, INV
Buist, Girbe, INV
Kuipers, Oscar, INV
Correspondence Address: TRASK BRITT, P.O. BOX 2550, SALT LAKE CITY, UT, 84110, US

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 20030180816	A1	20030925	US 2002321857	20021216
Continuation	UNKNOWN			WO 2002NL383	20020611
Priority				EP 2001202239	20010611

Fulltext Word Count: 17864

Abstract:
Methods for improving binding of a proteinaceous substance to cell-wall material of a Gram-positive bacterium are disclosed. The proteinaceous substance includes an AcmA cell-wall binding domain, homolog or functional derivative thereof. The method includes treating the cell-wall material with a solution capable of removing a cell-wall component such as a protein, lipoteichoic acid or carbohydrate from the cell-wall material and contacting the proteinaceous substance with the cell-wall material.

3/3,AB/6 (Item 1 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT

01097829
CONSERVED AND SPECIFIC STREPTOCOCCAL GENOMES
GENOMES DE STREPTOCOQUES CONSERVES OU SPECIFIQUES
Patent Applicant/Assignee:
CHIRON CORPORATION, 4560 Horton Street, Emeryville, CA 94608-2916, US, US (Residence), US (Nationality), (For all designated states except: US)
THE INSTITUTE FOR GENOMIC RESEARCH, 9712 Medical Center Drive, Rockville, MD 20850, US, US (Residence), US (Nationality), (For all designated states except: US)
Patent Applicant/Inventor:
TETTELIN Herve, c/o The Institute for Genomic Research, 9712 Medical Center Drive, Rockville, MD 20850, US, US (Residence), BE (Nationality), (Designated only for: US)
MASIGNANI Vega, c/o Chiron Corporation, 4560 Horton Street, Emeryville, CA 94608, US, IT (Residence), IT (Nationality), (Designated only for: US)
Legal Representative:
HALE Rebecca M (et al) (agent), Chiron Corporation, Intellectual Property

R338, P.O. Box 8097, Emeryville, CA 94662-8097, US,
Patent and Priority Information (Country, Number, Date):
Patent: WO 200418646 A2 20040304 (WO 0418646)
Application: WO 2003US26827 20030826 (PCT/WO US03026827)
Priority Application: US 2002406237 20020826; US 2002406676 20020827; US 2002406757 20020828
Parent Application/Grant:
Related by Continuation to: US 2002406237 20020826 (CIP); US 2002406676 20020827 (CIP); US 2002406757 20020828 (CIP)
Designated States:
(Protection type is "patent" unless otherwise stated - for applications prior to 2004)
AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW
(EP) AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR
(OA) BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
(EA) AM AZ BY KG KZ MD RU TJ TM
Publication Language: English
Filing Language: English
Fulltext Word Count: 297825
English Abstract
The invention relates to polynucleotides which are conserved or specific to one or more species of Streptococcus, Streptococcus species serotypes, and/or serotype isolates. In particular, the invention relates to polynucleotides from Streptococcus which are conserved or specific to one or more of the species of S. pneumoniae ("pneumococcus" or "S. pn."), S. pyogenes ("group A streptococcus" or "GAS"), and S. agalactiae ("group B streptococcus" or "GBS"). The invention further relates to polynucleotides which are conserved or specific to one or more Streptococcal species serotypes, such as GBS serotypes Ia, Ib, II, III, IV, V, VI, VII, and VIII. The invention still further relates to polynucleotides which are conserved or specific to one or more clinical isolates of a Streptococcus species.

French Abstract
Cette invention concerne des polynucleotides conserves ou specifiques d'une ou de plusieurs especes de streptocoques, de serotypes d'especes de streptocoques et/ou d'isolats de serotypes. L'invention concerne en particulier des polynucleotides de streptocoques qui sont conservee ou specifiques d'une ou de plusieurs especes de S. pneumoniae ("pneumococcus" ou "S. pn."), S. pyogenes ("streptocoques du groupe A" ou "GAS"), et S. agalactiae ("streptocoques du groupe B " ou "GBS"). L'invention concerne egalement des polynucleotides qui sont conserves ou specifiques d'un ou de plusieurs serotypes d'especes streptococciques, tels que les serotypes GBS Ia, Ib, II, III, IV, V, VI, VII, et VIII. L'invention concerne en outre des polynucleotides qui sont conserves ou specifiques d'un ou de plusieurs isolats cliniques d'une espece de streptocoque.

3/3,AB/7 (Item 2 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT

00968329
METHODS FOR BINDING ACMA-TYPE PROTEIN ANCHOR FUSIONS TO CELL-WALL MATERIAL OF MICRO-ORGANISMS
TECHNIQUE AMELIOREE PERMETTANT DE FIXER DES FUSIONS D'ANCRAGE DE PROTEINES DE TYPE ACMA A LA PAROI CELLULAIRE DE MICRO-ORGANISMES
Patent Applicant/Assignee:
APPLIED NANOSYSTEMS B V, Postbus 100, NL-9700 AC Groningen, NL, NL (Residence), NL (Nationality), (For all designated states except: US)
Patent Applicant/Inventor:
LEENHOUTS Cornelis Johannes, Tussenkoelen 6, NL-9753 KX Haren, NL, NL

(Residence), NL (Nationality), (Designated only for: US)
RAMASAMY Ranjan, 137/3 Kirula Road, Colombo 05, LK, LK (Residence), LK (Nationality), (Designated only for: US)
STEEN Anton, Zonland 143, NL-9734 BR Groningen, NL, NL (Residence), NL (Nationality), (Designated only for: US)
KOK Jan, Van Hamelstraat 34, NL-9714 HL Groningen, NL, NL (Residence), NL (Nationality), (Designated only for: US)
BUIST Girbe, Noordbroeksterstraat 88, NL-9611 BN Sappemeer, NL, NL (Residence), NL (Nationality), (Designated only for: US)
KUIPERS Oscar Paul, Lepelaar 95, NL-9728 XG Groningen, NL, NL (Residence), NL (Nationality), (Designated only for: US)
Legal Representative:
PRINS A W (agent), c/o Vereenigde, Nieuwe Parklaan 97, NL-2587 BN The Hague, NL,
Patent and Priority Information (Country, Number, Date):
Patent: WO 2002101026 A2-A3 20021219 (WO 02101026)
Application: WO 2002NL383 20020611 (PCT/WO NL02000383)
Priority Application: EP 2001202239 20010611
Designated States:
(Protection type is "patent" unless otherwise stated - for applications prior to 2004)
AE AG AL AM AT (utility model) AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ (utility model) CZ DE (utility model) DE DK (utility model) DK DM DZ EC EE (utility model) EE ES FI (utility model) FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK (utility model) SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
(OA) BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
(EA) AM AZ BY KG KZ MD RU TJ TM
Publication Language: English
Filing Language: English
Fulltext Word Count: 15714

English Abstract
The invention provides a method for binding of a proteinaceous substance to cell-wall material of a Gram-positive bacterium, said substance comprising an AcmA cell wall binding domain or homolog or functional derivative thereof, said method comprising treating said cell-wall material with a solution capable of removing a cell-wall component such as a protein, (lipo) teichoic acid or carbohydrate from said cell-wall-material and contacting said substance with said cell-wall material.

French Abstract
La presente invention concerne une technique permettant d'ameliorer la liaison d'une substance proteinique a la paroi cellulaire d'une bacterie Gram positif, cette substance comprenant un domaine de fixation de paroi de cellule AcmA ou un homologue ou un derive fonctionnel de celui-ci. Cette technique consiste a traiter cette paroi cellulaire avec une solution capable de retirer un element de cette paroi cellulaire tel qu'une proteine, un acide (lipo)teichoique ou un element glucidique de cette paroi et de mettre en contact cette substance avec cette paroi cellulaire.

3/3,AB/8 (Item 3 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT

00901997
NUCLEIC ACIDS AND PROTEINS FROM STREPTOCOCCUS GROUPS A & B
ACIDES NUCLEIQUES ET PROTEINES DERIVES DES GROUPES DE STREPTOCOQUES A ET B
Patent Applicant/Assignee:
CHIRON S P A, Via Fiorentina, 1, I-53100 Siena, IT, IT (Residence), IT (Nationality), (For all designated states except: US)
THE INSTITUTE FOR GENOMIC RESEARCH, 9712 Medical Center Drive, Rockville,

MD 20850, US, US (Residence), US (Nationality), (For all designated states except: US)
Patent Applicant/Inventor:
TELFORD John, Chiron S.p.a, Via Fiorentina, 1, I-53100 Siena, IT, IT (Residence), GB (Nationality), (Designated only for: US)
MASIGNANI Vega, Chiron S.p.a, Via Fiorentina, 1, I-53100 Siena, IT, IT (Residence), IT (Nationality), (Designated only for: US)
MARGARIT Y ROS Immaculada, Chiron S.p.a, Via Fiorentina, 1, I-53100 Siena, IT, IT (Residence), IT (Nationality), (Designated only for: US)
GRANDI Guido, Chiron S.p.a, Via Fiorentina, 1, I-53100 Siena, IT, IT (Residence), IT (Nationality), (Designated only for: US)
FRASER CLAIRE, The Institute for Genomic Research, 9712 Medical Center Drive, Rockville, MD 20850, US, US (Residence), US (Nationality), (Designated only for: US)
TETTELIN Herve, The Institute for Genomic Research, 9712 Medical Center Drive, Rockville, MD 20850, US, US (Residence), BE (Nationality), (Designated only for: US)
Legal Representative:
HALLYBONE Huw George (et al) (agent), Carpmaels & Ransford, 43 Bloomsbury Square, London WC1A 2RA, GB,
Patent and Priority Information (Country, Number, Date):
Patent: WO 200234771 A2-A3 20020502 (WO 0234771)
Application: WO 2001GB4789 20011029 (PCT/WO GB0104789)
Priority Application: GB 200026333 20001027; GB 200028727 20001124; GB 20015640 20010307
Designated States:
(Protection type is "patent" unless otherwise stated - for applications prior to 2004)
AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
(OA) BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZW
(EA) AM AZ BY KG KZ MD RU TJ TM
Publication Language: English
Filing Language: English
Fulltext Word Count: 1058437

English Abstract
The invention provides proteins from group B streptococcus (Streptococcus agalactiae) and group A streptococcus (Streptococcus pyogenes), including amino acid sequences and the corresponding nucleotide sequences. Data are given to show that the proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics. The proteins are also targets for antibiotics.

French Abstract
Cette invention se rapporte a des proteines derivees du streptocoque de groupe B (Streptococcus agalactiae) et du streptocoque de groupe A (Streptococcus pyogenes), y compris des sequences d'acides amines et les sequences de nucleotides correspondantes. On produit des donnees qui montrent que ces proteines constituent des antigenes utiles pour des vaccins, des compositions immunogenes et/ou des diagnostics. Ces proteines constituent egalement des cibles pour des antibiotiques.

3/3,AB/9 (Item 4 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT

00780221
PNEUMOCOCCAL VACCINES
VACCINS ANTIPNEUMOCOCCIQUES
Patent Applicant/Assignee:
ERASMUS UNIVERSITEIT ROTTERDAM, Dr. Molewaterplein 50, NL-5015 GE Rotterdam, NL, NL (Residence), NL (Nationality), (For all designated

states except: US)
Patent Applicant/Inventor:
DE GROOT Ronald, Jan Van Ghestellaan 45, NL-3045 CG Rotterdam, NL, NL (Residence), NL (Nationality), (Designated only for: US)
HERMANS Peter Wilhelmus Maria, Gortmolenerf 36, NL-2807 EJ Gouda, NL, NL (Residence), NL (Nationality), (Designated only for: US)
Legal Representative:
PRINS A W, Vereenigde, Nieuwe Parklaan 97, NL-2587 BN The Hague, NL
Patent and Priority Information (Country, Number, Date):
Patent: WO 200112219 A1 20010222 (WO 0112219)
Application: WO 2000NL569 20000814 (PCT/WO NL0000569)
Priority Application: EP 99202640 19990813
Designated States:
(Protection type is "patent" unless otherwise stated - for applications prior to 2004)
AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZW
(EA) AM AZ BY KG KZ MD RU TJ TM
Publication Language: English
Filing Language: English
Fulltext Word Count: 7578

English Abstract
The invention relates to the use of a protein or a fragment thereof of S. pneumoniae , its use for the preparation of a vaccine for the preventive treatment of a S. pneumoniae infection, compositions comprising %protease% %maturation% %protein% of S. pneumoniae infection, or a fragment thereof, vaccines comprising said protein or fragment thereof, use of a nucleic acid sequence encoding for said protein or fragment thereof, vectors wherein the nucleic acid sequence is brought to expression and to recombinant %protease% %maturation% %protein% or a fragment thereof or (functional) homologues thereof and to a method for the determination of proteins with opsonophagocytic activity and/or in vivo immunisation and/or in vivo immune protection.

French Abstract
L'invention concerne l'utilisation d'une proteine S. pneumoniae ou d'un fragment de celle-ci, son utilisation pour la preparation d'un vaccin pour le traitement preventif d'une infection a S. pneumoniae , des compositions comprenant la proteine de maturation de protease de S. pneumoniae ou un fragment de celle-ci, vaccins comprenant ladite proteine ou un fragment de celle-ci. L'invention porte egalement sur l'utilisation d'une sequence nucleotidique codant pour ladite proteine ou ledit fragment de celle-ci, sur des vecteurs dans lesquels l'expression de la sequence nucleotidique est transformee en proteine de maturation de protease recombinee, en un fragment de celle-ci ou en homologues (fonctionnels) de celle-ci. L'invention se rapporte encore a un procede de determination de proteines ayant une activite opsonophagocytique et/ou d'immunisation in vivo et/ou de protection immunitaire in vivo .

3/3,AB/10 (Item 5 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT

00336983
METHODS AND COMPOSITIONS FOR INHIBITION OF MEMBRANE FUSION-ASSOCIATED EVENTS, INCLUDING HIV TRANSMISSION
PROCEDES ET COMPOSITIONS POUR EMPECHER CERTAINS PHENOMENES ASSOCIES AVEC LA FUSION AVEC LA MEMBRANE, EN PARTICULIER LA TRANSMISSION DU VIH
Patent Applicant/Assignee:
DUKE UNIVERSITY,
TRIMERIS INC,

Inventor(s):
BOLOGNESI Dani P,
MATTHEWS Thomas J,
WILD Cart T,
BARNEY Shawn O'Lin,
LAMBERT Dennis M,
PETTEWAY Stephen R Jr,
LANGLOIS Alphonse J,
Patent and Priority Information (Country, Number, Date):
Patent: WO 9619495 A1 19960627
Application: WO 95US16733 19951220 (PCT/WO US9516733)
Priority Application: US 94107 19941220; US 95896 19950606
Designated States:
(Protection type is "patent" unless otherwise stated - for applications prior to 2004)
AL AM AU BB BG BR BY CA CN CZ EE FI GE HU IS JP KG KP KR KZ LK LR LS LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK TJ TM TT UA UZ VN KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG
Publication Language: English
Fulltext Word Count: 203630

English Abstract
The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention comprise DP178 (SEQ ID:1) peptide corresponding to amino acids 638 to 673 of the HIV-1LAI gp41 protein, and fragments, analogs and homologs of DP178. The invention further relates to the uses of such peptides as inhibitory of human and non-human retroviral, especially HIV, transmission to uninfected cells.

French Abstract
La presente invention concerne des peptides qui presentent une activite importante contre les retrovirus. Les peptides de l'invention comprennent le peptide DP178 (SEQ ID:1) correspondant aux acides amines 638 a 673 de la proteine VIH-1LAI gp41 et des fragments, analogues et homologues de DP178. L'invention concerne en outre l'utilisation de ces peptides comme inhibiteurs de la transmission a des cellules non infectees de retrovirus humains ou non humains, en particulier du VIH.

3/3,AB/11 (Item 1 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

01245487
Pneumococcal vaccines
Pneumokokkus Impfstoffe
Vaccins pneumococciques
PATENT ASSIGNEE:
Erasmus Universiteit Rotterdam, (517671), Dr. Molewaterplein 50, 3015 GE Rotterdam, (NL), (Applicant designated States: all)
INVENTOR:
de Groot, Ronald, Jan van Ghestellaan 45, 3045 CG Rotterdam, (NL)
Hermans, Peter Wilhelmus Maria, Gortmolenerf 36, 2807 EJ Gouda, (NL)
LEGAL REPRESENTATIVE:
Ottevangers, Sietse Ulbe et al (20841), Vereenigde, Postbus 87930, 2508 DH Den Haag, (NL)
PATENT (CC, No, Kind, Date): EP 1075841 A1 010214 (Basic)
APPLICATION (CC, No, Date): EP 99202640 990813;
DESIGNATED STATES: DE
EXTENDED DESIGNATED STATES: AL; LT; LV; MK; RO; SI
INTERNATIONAL PATENT CLASS: A61K-039/09; C07K-014/315; C12N-015/31; C07K-016/12; A61P-031/04

ABSTRACT EP 1075841 A1
The invention relates to the use of a protein or a fragment thereof of S. pneumoniae, its use for the preparation of a vaccine for the

preventive treatment of a S. pneumoniae infection, compositions comprising %protease% %maturation% %protein% of S. pneumoniae or a fragment thereof, vaccines comprising said protein or fragment thereof, use of a nucleic acid sequence encoding for said protein or fragment thereof, vectors wherein the nucleic acid sequence is brought to expression and to recombinant %protease% %maturation% %protein% or a fragment thereof.
ABSTRACT WORD COUNT: 86
NOTE:
Figure number on first page: NONE

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	200107	457
SPEC A	(English)	200107	5155
Total word count - document A			5612
Total word count - document B			0
Total word count - documents A + B			5612

3/3,AB/12 (Item 1 from file: 47)
DIALOG(R)File 47:Gale Group Magazine DB(TM)

06371065 SUPPLIER NUMBER: 76997548 (USE FORMAT 7 OR 9 FOR FULL TEXT)
Complete Genome Sequence of a Virulent Isolate of Streptococcus pneumoniae. (research) (Illustration) (Statistical Data Included)
Tettelin, Herve; Nelson, Karen E.; Paulsen, Ian T.; Eisen, Jonathan A.; Read, Timothy D.; Peterson, Scott; Heidelberg, John; DeBoy, Robert T.; Haft, Daniel H.; Dodson, Robert J.; Durkin, A. Scott; Gwinn, Michelle; Kolonay, James F.; Nelson, William C.; Peterson, Jeremy D.; Umayam, Lowell A.; White, Owen; Salzberg, Steven L.; Lewis, Matthew R.; Radune, Diana; Holtzapple, Erik; Khouri, Hoda; Wolf, Alex M.; Utterback, Terry R.; Hansen, Cheryl L; McDonald, Lisa A.; Feldblyum, Tamara V.; Angiuoli, Samuel; Dickinson, Tanja; Hickey, Erin K.; Holt, Ingeborg E.; Loftus, Brendan J.; Yang, Fan; Smith, Hamilton O.; Venter, J. Craig; Dougherty, Brian A.; Morrison, Donald A.; Hollingshead, Susan K.; Fraser, Claire M.
Science, 293, 5529, 498
July 20, 2001
DOCUMENT TYPE: Illustration Statistical Data Included ISSN: 0036-8075
LANGUAGE: English RECORD TYPE: Fulltext; Abstract
WORD COUNT: 6269 LINE COUNT: 00667

AUTHOR ABSTRACT: The 2,160,837--base pair genome sequence of an isolate of Streptococcus pneumoniae, a Gram-positive pathogen that causes pneumonia, bacteremia, meningitis, and otitis media, contains 2236 predicted coding regions; of these, 1440 (64%) were assigned a biological role. Approximately 5% of the genome is composed of insertion sequences that may contribute to genome rearrangements through uptake of foreign DNA. Extracellular enzyme systems for the metabolism of polysaccharides and hexosamines provide a substantial source of carbon and nitrogen for S. pneumoniae and also damage host tissues and facilitate colonization. A motif identified within the signal peptide of proteins is potentially involved in targeting these proteins to the cell surface of low--guanine/cytosine (GC) Gram-positive species. Several surface-exposed proteins that may serve as potential vaccine candidates were identified. Comparative genome hybridization with DNA arrays revealed strain differences in S. pneumoniae that could contribute to differences in virulence and antigenicity.
?